For this experiment, we chose to only use the TPV/Δ66R/mIL-2 recombinant as it had demonstrated efficacy IT for the reconstituted animals, and IV-delivered interleukin-2 has been FDA approved since 1998 for the treatment of stage IV metastatic melanoma [16]. Here, IL2 is linked to metastatic melanoma.